Skip to main content
Midas Edge

Cara Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

TVRD$1.41+47.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024

PART I –FINANCIAL INFORMATION

​​PAGENUMBER
​​​
Item 1.Financial Statements (Unaudited):​
​​​
​Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 20231
​​​
​Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 20232
​​​
​Condensed Consolidated Statements of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2024 and 20233
​​​
​Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 20235
​​​
​Notes to Condensed Consolidated Financial Statements6
​​​
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations34
​​​
Item 3.Quantitative and Qualitative Disclosures About Market Risk61
​​​
Item 4.Controls and Procedures62
​​​
​PART II – OTHER INFORMATION​
​​​
Item 1.Legal Proceedings63
​​​
Item 1A.Risk Factors63
​​​
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds106
​​​
Item 3.Defaults Upon Senior Securities106
​​​
Item 4.Mine Safety Disclosures106
​​​
Item 5.Other Information106
​​​
Item 6.Exhibits107
​​​
​SIGNATURES108

PART I

FINANCIAL INFORMATION

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.